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In  May  2006,  the  WHO  published  a Global  Pandemic  Inﬂuenza  Action  Plan.  A signiﬁcant  part  of  thataccine manufacture
ess  developed countries
echnology  transfer
plan  involves  the  transfer  of  technology  necessary  to  build  production  capacity  in  developing  countries.
The  WHO  inﬂuenza  technology  transfer  initiative  has  been  successful.  Clearly  the relatively  small  WHO
investments  made  in these  companies  to develop  their own  inﬂuenza  vaccine  production  facilities  have
had  quite  dramatic  results.  A  few companies  are  already  producing  large  amounts  of inﬂuenza  vaccine.
Others  will  soon  follow.  Whether  they are  developing  egg-based  or planning  non-egg  based  inﬂuenza
vaccine  production,  all  companies  are  optimistic  that  their  efforts  will  come  to  fruition.In May  2006, the World Health Organization (WHO) published
 Global Pandemic Inﬂuenza Action Plan to increase inﬂuenza vac-
ine supply for the world [1]. The overriding aim of the Action Plan
as to decrease the obvious shortfall between demand for a pan-
emic vaccine and the available production capacity if a severe
andemic should occur. A signiﬁcant part of the agenda focused
n building inﬂuenza vaccine production capacity in developing
ountries that would not otherwise have access to a pandemic vac-
ine to protect their populations. However, because of the lack of
now-how and production facilities for inﬂuenza vaccine in these
ountries, the need for considerable and expeditious technology
ransfer to build new production capacity becomes a major chal-
enge.
After receiving funds for inﬂuenza vaccine technology trans-
er, WHO  moved rapidly to make vaccine production a reality.
eveloping country vaccine manufacturers were systematically
ncouraged to submit proposals for inﬂuenza vaccine produc-
ion, and a process was set up to review the proposals. Central
o that review process was a WHO  internal coordinating group
n Geneva and an independent, international review committee,
ubbed the Technical Advisory Group (TAG). The eight members of
AG (Table 1), appointed in their personal capacity, have industrial
nﬂuenza vaccine production expertise and/or relevant regulatory
∗ Corresponding author. Tel.: +1 650 228 7909; fax: +1 650 228 7901.
E-mail  address: dfrancis@gsid.org (D.P. Francis).
1 Member of the World Health Organization Inﬂuenza Vaccine Technical Advisory
roup.
264-410X ©  2011 Elsevier Ltd. 
oi:10.1016/j.vaccine.2011.02.078
Open access under CC BY-NC-ND license.© 2011 Elsevier Ltd. 
experience that allows them to understand both the challenges
ahead of the applicants and the local, regional and global effects
and beneﬁts that the WHO  seed grants might have.
The review process starts with a public invitation on the WHO
web site for vaccine manufacturers to submit letters of intent
with a view to receiving a grant to develop capacity for pan-
demic inﬂuenza vaccine. The letters of intent are reviewed against
mandatory criteria, as well as against their technical merit, public
health value and potential regional impact. Eligible manufactur-
ers are invited to submit full proposals, which are scored, ranked
and weighted by TAG members according to an evaluation of ﬁve
elements: the project plan; the stafﬁng and management plan; per-
formance measures; an understanding of the requirements; and the
budget justiﬁcation. The technical evaluation is completed by a pro-
grammatic review, e.g. on government support and sustainability,
and by the results of site audits on production, Good Manufacturing
Practices, and biosafety requirements.
Two review processes were completed in 2008 and in 2009,
resulting in 11 awards (Table 2).
Once initial awards are made and the programme of work is
under way, members of the TAG make site visits to assess the
progress and gauge the value and use of the WHO  grant funds in
accomplishing the ultimate goal of assuring the access of develop-
ing country populations to a safe, effective and affordable pandemic
inﬂuenza vaccine. In addition, TAG members review the quarterly
reports submitted to WHO  by the grantees, and have access to a
dedicated, conﬁdential extranet sharepoint system elaborated by
Open access under CC BY-NC-ND license.WHO. Annual TAG meetings complement regular teleconferences
and often take place at one of the grantee sites, to provide an oppor-
tunity for hands-on interaction and coincide with meetings of all
the international partners.
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Table 1
Membership of the WHO  inﬂuenza vaccine technology transfer Technical Advisory
Group.
TAG member Particular expertise
John Boslego Vaccine production
Armen Donabedian Biotechnology
Donald Francis Production of viral vaccines
Gary  Grohmann Vaccine registration
Michael Perdue Inﬂuenza vaccine
Jim Robertson Inﬂuenza vaccine
T
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Of note is the broad spectrum of grant recipients. Vaccine
anufacturers range from large companies producing signiﬁcant
uantities of a broad range of vaccines to small- or medium-
ized organizations producing only basic products such as
iphtheria–pertussis–tetanus vaccine and are just now beginning
o expand into other vaccines. Interestingly, only two of the grant
ecipients are for-proﬁt companies, while nine are government-
ponsored organizations.
Almost  universally, the WHO  grants are small in relation to
he overall investment these companies are making in inﬂuenza
accine production. But commonly, the grantees express that the
eneﬁt of having WHO  involved, both via ﬁnance and expertise, has
ar more value than the monetary support alone. This value comes
irectly from the relative freedom of using WHO  funds as well as
ndirectly from the endorsement of WHO  of the applicant’s overall
nﬂuenza plans, approaches and efforts. The latter gives other fun-
ers, especially their own governments, conﬁdence that the quality
f effort is of a high standard.
Furthermore,  independent, external WHO  reviews of the
rojects help assure companies and governments that their invest-
ent is wise, reasonably managed and that the probability ofechnical success is high. Indeed, these reviews, carried out by WHO
nd TAG members, prove valuable from many vantages. From a
HO  vantage, it gives the Organization and its funders evidence
hat the money is being well invested and used. But probably more
able 2
ist  of WHO  grantees by country, manufacturer and private/public status.
Country Institute (Legal status) 
2008 grantees
Brazil Instituto Butantan (Public)
India Serum Institute of India (Private) 
Indonesia Bio Farma (Public) 
Mexico  Birmex (Public) 
Thailand Government Pharmaceutical Organiza
Viet  Nam Institute of Vaccines and Medical Biol
2009 grantees
Egypt Vacsera (Public) 
Islamic Republic of Iran Razi Institute (Public) 
Republic of Korea Green Cross Corporation (Private) 
Romania  Cantacuzino Institute (Public) 
Serbia Torlak (Public) Jean-Francois Saluzzo Production of viral vaccines
Jaspal  Sokhey Regulatory  issues and vaccine production
important is the value and conﬁdence that such reviews give to the
local employees working on the projects, as most reviews have been
supportive of the development plans submitted by the applicants.
Certainly there have been recommendations for some changes,
but often the WHO/TAG teams have given support to “carry on
as planned”. This gives recipients additional reassurance to pro-
ceed and conﬁrms for the executive management that their teams
know what they are doing. This is important because of the unique
complexities of inﬂuenza vaccine manufacture. Large egg-based
production facilities are a new concept for most applicants. To sup-
port such production, many recipients have even had to develop
their own egg supply facilities. Moreover, most of the countries
Technology
Egg-based inactivated split and/or
whole virion H5N1 with adjuvant,
based on transfer of seasonal
production  technology
Egg-based technologies: (i) whole
virion alum-adjuvanted inactivated
vaccine, and (ii) live attenuated
inﬂuenza  vaccine using WHO
sublicensed Russian technology
A ﬁll-ﬁnish facility and upstream
vaccine antigen production unit
through adoption of Japanese
technology for seasonal vaccine: split
egg-based product
Egg-based split vaccine. Establishment
of a blending, ﬁlling and packaging
facility as a ﬁrst step using imported
antigens
tion (Public) Egg-based technologies: (i)
establishment of an egg-based split
inactivated seasonal vaccine process,
and (ii) live attenuated inﬂuenza
vaccine using WHO  sublicensed
Russian  technology
ogicals (Public) Small-scale production facility for the
production of egg-derived whole virion
and alum adjuvanted H5N1 and H1N1
inﬂuenza vaccines; and a small-scale
chicken farm for clean egg supply
Small-scale facility to produce
egg-derived  whole virion inﬂuenza
vaccine
Egg-based inﬂuenza vaccines in
small-scale facility
Establishment of dedicated plant for
alum adjuvanted whole virion H5N1
inﬂuenza vaccine
Pilot-scale production of seasonal
egg-based inactivated split inﬂuenza
vaccine
Construction of a new ﬁlling
department
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nvolved have not had established inﬂuenza vaccine delivery pro-
rammes and have therefore had to make plans for vaccine delivery
n parallel to building their own indigenous production facilities.
Interestingly, only 3 of the 11 grant recipients are developing
nﬂuenza production facilities in partnership with large interna-
ional pharmaceutical companies (Instituto Butantan, Brazil and
irmex, Mexico with sanoﬁ pasteur and Bio Farma, Indonesia
ith Biken). Independent of WHO, these recipients have made
heir own business arrangements with their technology transfer
artner either to construct production facilities or to share the pro-
uction, ﬁll ﬁnish or other components of the larger production
rocess.
Given that few of the grantees had previous experience of
nﬂuenza vaccine development and manufacture, they all required
raining, although the extent of the training varies by grantee.
or this purpose, WHO  has established a centre of excellence
nd training at the Netherlands Vaccine Institute in Bilthoven,
he Netherlands [2]. Feedback from the grantees indicates that
he training courses carried out here and/or at the National Insti-
ute for Biological Standards and Control in the United Kingdom
ave been instrumental for the successful implementation of the
rojects.
The hope that the WHO  grants will also stimulate new non-egg
roduction methodologies remains. Although the recent H1N1
pidemic forced some recipients to go straight into egg-based
andemic inﬂuenza vaccine production, there is continued inter-
st from several companies to invest in alternative production
echniques.
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In summary, as viewed from the vantage of the TAG, the WHO
inﬂuenza technology transfer initiative has been successful. Clearly
the relatively small WHO  investments made in these companies to
develop their own inﬂuenza vaccine production facilities have had
quite dramatic results. A few companies are already producing large
amounts of inﬂuenza vaccine. Others will soon follow. Whether
they are developing egg-based or planning non-egg based inﬂuenza
vaccine production, all companies are optimistic that their efforts
will come to fruition.
Some  positive effects of the WHO  technology transfer initia-
tive were not anticipated. Importantly, the interest in combating
pandemic inﬂuenza at national and regional levels, with the assis-
tance of WHO  grants to stimulate local production, has resulted in a
variety of indigenous ﬁnancing mechanisms that will dramatically
improve the supply of inﬂuenza vaccines in the future. Moreover,
interest in inﬂuenza seems to have rekindled interest in the local
production of essential vaccines in several countries. This could
have a major impact on the future health of populations in these
countries.
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